Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To determine the toxicity profile and tolerability of alemtuzumab (Campath) when
administered in combination with cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) chemotherapy (C-CHOP) in patients with T-cell, null-cell and NK-cell
lymphomas.
Secondary Objectives:
- To evaluate response rate, overall survival, and disease-free survival in patients with
T-cell, null-cell, and NK-cell lymphomas treated with Campath + CHOP chemotherapy.
- To assess the incidence of cytomegalovirus (CMV) reactivation in patients with these
lymphomas treated with the Campath + CHOP combination.
- To determine features which might be predictive of resistance to treatment or predictive
of relapse, including the absence of glycosylphosphatidylinositol (GPI)-linked proteins.